← Back to Search

Treatment for Cytomegalovirus

N/A
Waitlist Available
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1-year after index date
Awards & highlights

Summary

The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe \[EU\] and Canada \[CAN\]). Data will be collected retrospectively from medical charts. No study medicines will be provided to participants in this study.

Eligible Conditions
  • Cytomegalovirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1-year after index date
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1-year after index date for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Genetic Mutations Conferring Anti-CMV Resistance From HSCT and at Index Episode
Percentage of Participants With Anti-CMV Treatment-related Myelosuppression and Nephrotoxicity
Percentage of Participants With CMV Viremia Clearance as Defined by Site Investigator at 1-year After Index Date
+20 more
Secondary study objectives
Duration of Anti-CMV Prophylaxis Therapy
Duration of Anti-CMV Therapy During CMV Episodes
Duration of Stay in Critical Care and Non-critical Care
+17 more

Find a Location

Who is running the clinical trial?

TakedaLead Sponsor
1,227 Previous Clinical Trials
4,222,387 Total Patients Enrolled
Study DirectorStudy DirectorTakeda
1,252 Previous Clinical Trials
504,261 Total Patients Enrolled
~52 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top